APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phage Therapy

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

Selected research

Market Analysis & Forecast

Global Phage Therapy Market Analysis and Forecast 2026-2032

29 December 2025212 pages

Choose your research edition.

Industry ResearchPhage Therapy Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Phage Therapy Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Phage Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phage Therapy Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Phage Therapy Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

The major players in global Phage Therapy market include NPO Microgen, Proteon Pharmaceuticals, Phagelux, etc. The top 3 players occupy about 25% shares of the global market. North America and Europe are main markets, they occupy about 60% of the global market. DsDNA Bacteriophage is the main type, with a share over 90%. Animal Health is the main application, which holds a share about 55%.

Report Includes

Read the full market overview

This report presents an overview of global market for Phage Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Phage Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Phage Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Phage Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Phage Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Phage Therapy revenue, projected growth trends, production technology, application and end-user industry.

Phage Therapy Segment by Company

NPO Microgen

Proteon Pharmaceuticals

Phagelux

Intralytix

Micreos

Eliava BioPreparations

Locus Biosciences,Inc

Pharmex Group,LLC

Pherecydes Pharma

APS Biocontrol Ltd. (APS)

Qingdao Phagepharm Bio-tech

Fixed-Phage Limited

Zeptometrix

Phage International, Inc.

MicroMir

iNtODEWORLD, Inc.

NEXTBIOTICS

Armata Pharmaceuticals, Inc.

Innophage

Adaptive Phage Therapeutics

TechnoPhage

Phage Therapy Segment by Type

DsDNA Bacteriophage

SsDNA Bacteriophage

SsRNA Bacteriophage

Others

Phage Therapy Segment by Application

Animal Health

Aquaculture

Agriculture

Food Industry

Human Health

Others

Phage Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phage Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phage Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phage Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Phage Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Phage Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phage Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Phage Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DsDNA Bacteriophage Major Player Table 3. SsDNA Bacteriophage Major Player Table 4. SsRNA Bacteriophage Major Player Table 5. Others Major Player Table 6. Global Phage Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Animal Health Major Player Table 8. Aquaculture Major Player Table 9. Agriculture Major Player Table 10. Food Industry Major Player Table 11. Human Health Major Player Table 12. Others Major Player Table 13. Phage Therapy Industry Trends Table 14. Phage Therapy Industry Drivers Table 15. Phage Therapy Industry Opportunities and Challenges Table 16. Phage Therapy Industry Restraints Table 17. Global Phage Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Phage Therapy Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Phage Therapy Market Share by Region (2021-2026) Table 20. Global Phage Therapy Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Phage Therapy Market Share by Region (2027-2032) Table 22. Global Phage Therapy Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Phage Therapy Revenue Market Share by Players (2021-2026) Table 24. Global Phage Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Phage Therapy Key Players Headquarters & Area Served Table 26. Global Phage Therapy Players, Product Type & Application Table 27. Global Phage Therapy Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Phage Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Phage Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Phage Therapy Revenue Market Share by Type (2021-2026) Table 34. Global Phage Therapy Revenue Market Share by Type (2027-2032) Table 35. Global Phage Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Phage Therapy Revenue Market Share by Application (2021-2026) Table 39. Global Phage Therapy Revenue Market Share by Application (2027-2032) Table 40. NPO Microgen Company Information Table 41. NPO Microgen Business Overview Table 42. NPO Microgen Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. NPO Microgen Phage Therapy Product Portfolio Table 44. NPO Microgen Recent Development Table 45. Proteon Pharmaceuticals Company Information Table 46. Proteon Pharmaceuticals Business Overview Table 47. Proteon Pharmaceuticals Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Proteon Pharmaceuticals Phage Therapy Product Portfolio Table 49. Proteon Pharmaceuticals Recent Development Table 50. Phagelux Company Information Table 51. Phagelux Business Overview Table 52. Phagelux Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Phagelux Phage Therapy Product Portfolio Table 54. Phagelux Recent Development Table 55. Intralytix Company Information Table 56. Intralytix Business Overview Table 57. Intralytix Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Intralytix Phage Therapy Product Portfolio Table 59. Intralytix Recent Development Table 60. Micreos Company Information Table 61. Micreos Business Overview Table 62. Micreos Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Micreos Phage Therapy Product Portfolio Table 64. Micreos Recent Development Table 65. Eliava BioPreparations Company Information Table 66. Eliava BioPreparations Business Overview Table 67. Eliava BioPreparations Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Eliava BioPreparations Phage Therapy Product Portfolio Table 69. Eliava BioPreparations Recent Development Table 70. Locus Biosciences,Inc Company Information Table 71. Locus Biosciences,Inc Business Overview Table 72. Locus Biosciences,Inc Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Locus Biosciences,Inc Phage Therapy Product Portfolio Table 74. Locus Biosciences,Inc Recent Development Table 75. Pharmex Group,LLC Company Information Table 76. Pharmex Group,LLC Business Overview Table 77. Pharmex Group,LLC Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Pharmex Group,LLC Phage Therapy Product Portfolio Table 79. Pharmex Group,LLC Recent Development Table 80. Pherecydes Pharma Company Information Table 81. Pherecydes Pharma Business Overview Table 82. Pherecydes Pharma Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Pherecydes Pharma Phage Therapy Product Portfolio Table 84. Pherecydes Pharma Recent Development Table 85. APS Biocontrol Ltd. (APS) Company Information Table 86. APS Biocontrol Ltd. (APS) Business Overview Table 87. APS Biocontrol Ltd. (APS) Phage Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. APS Biocontrol Ltd. (APS) Phage Therapy Product Portfolio Table 89. APS Biocontrol Ltd. (APS) Recent Development Table 90. Qingdao Phagepharm Bio-tech Company Information Table 91. Qingdao Phagepharm Bio-tech Business Overview Table 92. Qingdao Phagepharm Bio-tech Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Qingdao Phagepharm Bio-tech Phage Therapy Product Portfolio Table 94. Qingdao Phagepharm Bio-tech Recent Development Table 95. Fixed-Phage Limited Company Information Table 96. Fixed-Phage Limited Business Overview Table 97. Fixed-Phage Limited Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Fixed-Phage Limited Phage Therapy Product Portfolio Table 99. Fixed-Phage Limited Recent Development Table 100. Zeptometrix Company Information Table 101. Zeptometrix Business Overview Table 102. Zeptometrix Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Zeptometrix Phage Therapy Product Portfolio Table 104. Zeptometrix Recent Development Table 105. Phage International, Inc. Company Information Table 106. Phage International, Inc. Business Overview Table 107. Phage International, Inc. Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Phage International, Inc. Phage Therapy Product Portfolio Table 109. Phage International, Inc. Recent Development Table 110. MicroMir Company Information Table 111. MicroMir Business Overview Table 112. MicroMir Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. MicroMir Phage Therapy Product Portfolio Table 114. MicroMir Recent Development Table 115. iNtODEWORLD, Inc. Company Information Table 116. iNtODEWORLD, Inc. Business Overview Table 117. iNtODEWORLD, Inc. Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. iNtODEWORLD, Inc. Phage Therapy Product Portfolio Table 119. iNtODEWORLD, Inc. Recent Development Table 120. NEXTBIOTICS Company Information Table 121. NEXTBIOTICS Business Overview Table 122. NEXTBIOTICS Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. NEXTBIOTICS Phage Therapy Product Portfolio Table 124. NEXTBIOTICS Recent Development Table 125. Armata Pharmaceuticals, Inc. Company Information Table 126. Armata Pharmaceuticals, Inc. Business Overview Table 127. Armata Pharmaceuticals, Inc. Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Armata Pharmaceuticals, Inc. Phage Therapy Product Portfolio Table 129. Armata Pharmaceuticals, Inc. Recent Development Table 130. Innophage Company Information Table 131. Innophage Business Overview Table 132. Innophage Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Innophage Phage Therapy Product Portfolio Table 134. Innophage Recent Development Table 135. Adaptive Phage Therapeutics Company Information Table 136. Adaptive Phage Therapeutics Business Overview Table 137. Adaptive Phage Therapeutics Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Adaptive Phage Therapeutics Phage Therapy Product Portfolio Table 139. Adaptive Phage Therapeutics Recent Development Table 140. TechnoPhage Company Information Table 141. TechnoPhage Business Overview Table 142. TechnoPhage Phage Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. TechnoPhage Phage Therapy Product Portfolio Table 144. TechnoPhage Recent Development Table 145. North America Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 146. North America Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 147. North America Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 148. North America Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 149. North America Phage Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Phage Therapy Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Phage Therapy Revenue by Country (US$ Million) & (2027-2032) Table 152. Europe Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Phage Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe Phage Therapy Revenue by Country (2021-2026) & (US$ Million) Table 158. Europe Phage Therapy Revenue by Country (US$ Million) & (2027-2032) Table 159. China Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 160. China Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 161. China Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 162. China Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 166. Asia Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 167. Asia Phage Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia Phage Therapy Revenue by Region (US$ Million) & (2021-2026) Table 169. Asia Phage Therapy Revenue by Region (US$ Million) & (2027-2032) Table 170. SAMEA Phage Therapy Revenue by Type (2021-2026) & (US$ Million) Table 171. SAMEA Phage Therapy Revenue by Type (2027-2032) & (US$ Million) Table 172. SAMEA Phage Therapy Revenue by Application (2021-2026) & (US$ Million) Table 173. SAMEA Phage Therapy Revenue by Application (2027-2032) & (US$ Million) Table 174. SAMEA Phage Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. SAMEA Phage Therapy Revenue by Country (2021-2026) & (US$ Million) Table 176. SAMEA Phage Therapy Revenue by Country (US$ Million) & (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Phage Therapy Image Figure 2. Global Phage Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phage Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. DsDNA Bacteriophage Image Figure 5. SsDNA Bacteriophage Image Figure 6. SsRNA Bacteriophage Image Figure 7. Others Image Figure 8. Global Phage Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Phage Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Animal Health Image Figure 11. Aquaculture Image Figure 12. Agriculture Image Figure 13. Food Industry Image Figure 14. Human Health Image Figure 15. Others Image Figure 16. Global Phage Therapy Market Size (US$ Million) & (2021-2032) Figure 17. Global Phage Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Phage Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Phage Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Phage Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Phage Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Phage Therapy Revenue Market Share by Type (2021-2032) Figure 24. Global Phage Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Phage Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Phage Therapy Revenue Market Share by Application (2021-2032) Figure 27. North America Phage Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Phage Therapy Revenue Share by Type (2021-2032) Figure 29. North America Phage Therapy Revenue Share by Application (2021-2032) Figure 30. North America Phage Therapy Revenue Share by Country (2021-2032) Figure 31. United States Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Phage Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Phage Therapy Revenue Share by Type (2021-2032) Figure 36. Europe Phage Therapy Revenue Share by Application (2021-2032) Figure 37. Europe Phage Therapy Revenue Share by Country (2021-2032) Figure 38. Germany Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Phage Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Phage Therapy Revenue Share by Type (2021-2032) Figure 48. China Phage Therapy Revenue Share by Application (2021-2032) Figure 49. Asia Phage Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Phage Therapy Revenue Share by Type (2021-2032) Figure 51. Asia Phage Therapy Revenue Share by Application (2021-2032) Figure 52. Asia Phage Therapy Revenue Share by Region (2021-2032) Figure 53. Japan Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Phage Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Phage Therapy Revenue Share by Type (2021-2032) Figure 61. SAMEA Phage Therapy Revenue Share by Application (2021-2032) Figure 62. SAMEA Phage Therapy Revenue Share by Country (2021-2032) Figure 63. Brazil Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Phage Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • DsDNA Bacteriophage
  • SsDNA Bacteriophage
  • SsRNA Bacteriophage
  • Others
Applications
  • Animal Health
  • Aquaculture
  • Agriculture
  • Food Industry
  • Human Health
  • Others
Companies covered
  • NPO Microgen
  • Proteon Pharmaceuticals
  • Phagelux
  • Intralytix
  • Micreos
  • Eliava BioPreparations
  • Locus Biosciences,Inc
  • Pharmex Group,LLC
  • Pherecydes Pharma
  • APS Biocontrol Ltd. (APS)
  • Qingdao Phagepharm Bio-tech
  • Fixed-Phage Limited
  • Zeptometrix
  • Phage International, Inc.
  • MicroMir
  • iNtODEWORLD, Inc.
  • NEXTBIOTICS
  • Armata Pharmaceuticals, Inc.
  • Innophage
  • Adaptive Phage Therapeutics
  • TechnoPhage

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Phage Therapy Market by Type
  3. 1.2.1 Global Phage Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DsDNA Bacteriophage
  5. 1.2.3 SsDNA Bacteriophage
  6. 1.2.4 SsRNA Bacteriophage
  7. 1.2.5 Others
  8. 1.3 Phage Therapy Market by Application
  9. 1.3.1 Global Phage Therapy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Animal Health
  11. 1.3.3 Aquaculture
  12. 1.3.4 Agriculture
  13. 1.3.5 Food Industry
  14. 1.3.6 Human Health
  15. 1.3.7 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Phage Therapy Market Dynamics
  1. 2.1 Phage Therapy Industry Trends
  2. 2.2 Phage Therapy Industry Drivers
  3. 2.3 Phage Therapy Industry Opportunities and Challenges
  4. 2.4 Phage Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Phage Therapy Market Perspective (2021-2032)
  2. 3.2 Global Phage Therapy Growth Trends by Region
  3. 3.2.1 Global Phage Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Phage Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Phage Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Phage Therapy Revenue by Players
  2. 4.1.1 Global Phage Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Phage Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Phage Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Phage Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Phage Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Phage Therapy Players, Product Type & Application
  8. 4.5 Global Phage Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Phage Therapy Market CR5 and HHI
  11. 4.6.3 2025 Phage Therapy Tier 1, Tier 2, and Tier 3
5 Phage Therapy Market Size by Type
  1. 5.1 Global Phage Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Phage Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Phage Therapy Revenue Market Share by Type (2021-2032)
6 Phage Therapy Market Size by Application
  1. 6.1 Global Phage Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Phage Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Phage Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 NPO Microgen
  2. 7.1.1 NPO Microgen Company Information
  3. 7.1.2 NPO Microgen Business Overview
  4. 7.1.3 NPO Microgen Phage Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 NPO Microgen Phage Therapy Product Portfolio
  6. 7.1.5 NPO Microgen Recent Developments
  7. 7.2 Proteon Pharmaceuticals
  8. 7.2.1 Proteon Pharmaceuticals Company Information
  9. 7.2.2 Proteon Pharmaceuticals Business Overview
  10. 7.2.3 Proteon Pharmaceuticals Phage Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Proteon Pharmaceuticals Phage Therapy Product Portfolio
  12. 7.2.5 Proteon Pharmaceuticals Recent Developments
  13. 7.3 Phagelux
  14. 7.3.1 Phagelux Company Information
  15. 7.3.2 Phagelux Business Overview
  16. 7.3.3 Phagelux Phage Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Phagelux Phage Therapy Product Portfolio
  18. 7.3.5 Phagelux Recent Developments
  19. 7.4 Intralytix
  20. 7.4.1 Intralytix Company Information
  21. 7.4.2 Intralytix Business Overview
  22. 7.4.3 Intralytix Phage Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Intralytix Phage Therapy Product Portfolio
  24. 7.4.5 Intralytix Recent Developments
  25. 7.5 Micreos
  26. 7.5.1 Micreos Company Information
  27. 7.5.2 Micreos Business Overview
  28. 7.5.3 Micreos Phage Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Micreos Phage Therapy Product Portfolio
  30. 7.5.5 Micreos Recent Developments
  31. 7.6 Eliava BioPreparations
  32. 7.6.1 Eliava BioPreparations Company Information
  33. 7.6.2 Eliava BioPreparations Business Overview
  34. 7.6.3 Eliava BioPreparations Phage Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eliava BioPreparations Phage Therapy Product Portfolio
  36. 7.6.5 Eliava BioPreparations Recent Developments
  37. 7.7 Locus Biosciences,Inc
  38. 7.7.1 Locus Biosciences,Inc Company Information
  39. 7.7.2 Locus Biosciences,Inc Business Overview
  40. 7.7.3 Locus Biosciences,Inc Phage Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Locus Biosciences,Inc Phage Therapy Product Portfolio
  42. 7.7.5 Locus Biosciences,Inc Recent Developments
  43. 7.8 Pharmex Group,LLC
  44. 7.8.1 Pharmex Group,LLC Company Information
  45. 7.8.2 Pharmex Group,LLC Business Overview
  46. 7.8.3 Pharmex Group,LLC Phage Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pharmex Group,LLC Phage Therapy Product Portfolio
  48. 7.8.5 Pharmex Group,LLC Recent Developments
  49. 7.9 Pherecydes Pharma
  50. 7.9.1 Pherecydes Pharma Company Information
  51. 7.9.2 Pherecydes Pharma Business Overview
  52. 7.9.3 Pherecydes Pharma Phage Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pherecydes Pharma Phage Therapy Product Portfolio
  54. 7.9.5 Pherecydes Pharma Recent Developments
  55. 7.10 APS Biocontrol Ltd. (APS)
  56. 7.10.1 APS Biocontrol Ltd. (APS) Company Information
  57. 7.10.2 APS Biocontrol Ltd. (APS) Business Overview
  58. 7.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 APS Biocontrol Ltd. (APS) Phage Therapy Product Portfolio
  60. 7.10.5 APS Biocontrol Ltd. (APS) Recent Developments
  61. 7.11 Qingdao Phagepharm Bio-tech
  62. 7.11.1 Qingdao Phagepharm Bio-tech Company Information
  63. 7.11.2 Qingdao Phagepharm Bio-tech Business Overview
  64. 7.11.3 Qingdao Phagepharm Bio-tech Phage Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Qingdao Phagepharm Bio-tech Phage Therapy Product Portfolio
  66. 7.11.5 Qingdao Phagepharm Bio-tech Recent Developments
  67. 7.12 Fixed-Phage Limited
  68. 7.12.1 Fixed-Phage Limited Company Information
  69. 7.12.2 Fixed-Phage Limited Business Overview
  70. 7.12.3 Fixed-Phage Limited Phage Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Fixed-Phage Limited Phage Therapy Product Portfolio
  72. 7.12.5 Fixed-Phage Limited Recent Developments
  73. 7.13 Zeptometrix
  74. 7.13.1 Zeptometrix Company Information
  75. 7.13.2 Zeptometrix Business Overview
  76. 7.13.3 Zeptometrix Phage Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Zeptometrix Phage Therapy Product Portfolio
  78. 7.13.5 Zeptometrix Recent Developments
  79. 7.14 Phage International, Inc.
  80. 7.14.1 Phage International, Inc. Company Information
  81. 7.14.2 Phage International, Inc. Business Overview
  82. 7.14.3 Phage International, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Phage International, Inc. Phage Therapy Product Portfolio
  84. 7.14.5 Phage International, Inc. Recent Developments
  85. 7.15 MicroMir
  86. 7.15.1 MicroMir Company Information
  87. 7.15.2 MicroMir Business Overview
  88. 7.15.3 MicroMir Phage Therapy Revenue and Gross Margin (2021-2026)
  89. 7.15.4 MicroMir Phage Therapy Product Portfolio
  90. 7.15.5 MicroMir Recent Developments
  91. 7.16 iNtODEWORLD, Inc.
  92. 7.16.1 iNtODEWORLD, Inc. Company Information
  93. 7.16.2 iNtODEWORLD, Inc. Business Overview
  94. 7.16.3 iNtODEWORLD, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  95. 7.16.4 iNtODEWORLD, Inc. Phage Therapy Product Portfolio
  96. 7.16.5 iNtODEWORLD, Inc. Recent Developments
  97. 7.17 NEXTBIOTICS
  98. 7.17.1 NEXTBIOTICS Company Information
  99. 7.17.2 NEXTBIOTICS Business Overview
  100. 7.17.3 NEXTBIOTICS Phage Therapy Revenue and Gross Margin (2021-2026)
  101. 7.17.4 NEXTBIOTICS Phage Therapy Product Portfolio
  102. 7.17.5 NEXTBIOTICS Recent Developments
  103. 7.18 Armata Pharmaceuticals, Inc.
  104. 7.18.1 Armata Pharmaceuticals, Inc. Company Information
  105. 7.18.2 Armata Pharmaceuticals, Inc. Business Overview
  106. 7.18.3 Armata Pharmaceuticals, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Armata Pharmaceuticals, Inc. Phage Therapy Product Portfolio
  108. 7.18.5 Armata Pharmaceuticals, Inc. Recent Developments
  109. 7.19 Innophage
  110. 7.19.1 Innophage Company Information
  111. 7.19.2 Innophage Business Overview
  112. 7.19.3 Innophage Phage Therapy Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Innophage Phage Therapy Product Portfolio
  114. 7.19.5 Innophage Recent Developments
  115. 7.20 Adaptive Phage Therapeutics
  116. 7.20.1 Adaptive Phage Therapeutics Company Information
  117. 7.20.2 Adaptive Phage Therapeutics Business Overview
  118. 7.20.3 Adaptive Phage Therapeutics Phage Therapy Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Adaptive Phage Therapeutics Phage Therapy Product Portfolio
  120. 7.20.5 Adaptive Phage Therapeutics Recent Developments
  121. 7.21 TechnoPhage
  122. 7.21.1 TechnoPhage Company Information
  123. 7.21.2 TechnoPhage Business Overview
  124. 7.21.3 TechnoPhage Phage Therapy Revenue and Gross Margin (2021-2026)
  125. 7.21.4 TechnoPhage Phage Therapy Product Portfolio
  126. 7.21.5 TechnoPhage Recent Developments
8 North America
  1. 8.1 North America Phage Therapy Revenue (2021-2032)
  2. 8.2 North America Phage Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Phage Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Phage Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Phage Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Phage Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Phage Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Phage Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Phage Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Phage Therapy Revenue by Country
  11. 8.6.1 North America Phage Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Phage Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Phage Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Phage Therapy Revenue (2021-2032)
  2. 9.2 Europe Phage Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Phage Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Phage Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Phage Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Phage Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Phage Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Phage Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Phage Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Phage Therapy Revenue by Country
  11. 9.6.1 Europe Phage Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Phage Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Phage Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Phage Therapy Revenue (2021-2032)
  2. 10.2 China Phage Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Phage Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Phage Therapy Revenue by Type (2027-2032)
  5. 10.3 China Phage Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Phage Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Phage Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Phage Therapy Revenue by Application (2027-2032)
  9. 10.5 China Phage Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Phage Therapy Revenue (2021-2032)
  2. 11.2 Asia Phage Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Phage Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Phage Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Phage Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Phage Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Phage Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Phage Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Phage Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Phage Therapy Revenue by Country
  11. 11.6.1 Asia Phage Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Phage Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Phage Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Phage Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Phage Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Phage Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Phage Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Phage Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Phage Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Phage Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Phage Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Phage Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Phage Therapy Revenue by Country
  11. 12.6.1 SAMEA Phage Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Phage Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Phage Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst